^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cyclosporin A microemulsion

    i
    Other names: OLO400, OLO-400, OLO 400
    Company:
    Generic mfg.
    Drug class:
    Calcineurin inhibitor
    Related drugs:
    8d
    Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies (clinicaltrials.gov)
    P2/3, N=64, Recruiting, Federal Research Institute of Pediatric Hematology, Oncology and Immunology
    New P2/3 trial
    |
    Jakafi (ruxolitinib) • sirolimus • cyclosporin A microemulsion
    19d
    A Study of Romiplostim N01 Plus IST vs. Placebo Plus IST for Treatment-Naive Severe Aplastic Anemia (clinicaltrials.gov)
    P3, N=210, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
    New P3 trial
    |
    cyclosporin A microemulsion • Nplate (romiplostim) • Rui Lisheng (romiplostim biosimilar)
    24d
    Inhibition of LDHA promotes GSDME-dependent pyroptosis by activating RIG-I-like receptor signaling. (PubMed, Apoptosis)
    Here, a novel combination therapy consisting of the calcineurin inhibitor cyclosporine A (CsA) and the flavone-naphthalimide-polyamine derivative 6c was identified...Finally, combination of CsA and 6c suppressed tumor growth and pulmonary metastasis in vivo. Overall, our study suggests a novel synergistic treatment combination with a comprehensive mechanistic exploration, demonstrating that it is a promising strategy for HCC treatment via targeting RIG-I-like receptor signaling.
    Journal
    |
    LDHA (Lactate dehydrogenase A) • IFIH1 (Interferon Induced With Helicase C Domain 1) • GSDME (Gasdermin E) • IRF3 (Interferon Regulatory Factor 3) • TBK1 (TANK Binding Kinase 1)
    |
    cyclosporin A microemulsion
    25d
    Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, Boston Children's Hospital | Trial primary completion date: Jul 2025 --> Jul 2026
    Trial primary completion date
    |
    TERT (Telomerase Reverse Transcriptase) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • DKC1 (Dyskerin Pseudouridine Synthase 1) • ZCCHC8 (Zinc Finger CCHC-Type Containing 8) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Campath (alemtuzumab) • fludarabine IV • cyclosporin A microemulsion
    27d
    Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders (clinicaltrials.gov)
    P2, N=31, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    KMT2A (Lysine Methyltransferase 2A)
    |
    MLL rearrangement
    |
    clofarabine • fludarabine IV • busulfan • cyclosporin A microemulsion
    1m
    Concurrent Presentation of Pure Red Cell Aplasia and Myeloproliferative Neoplasm, Unclassifiable With JAK2 and MPL Mutations. (PubMed, Case Rep Hematol)
    The use of ruxolitinib and cyclosporin A has been shown to be beneficial for such patients. And the use of ruxolitinib decreases the dosage of cyclosporin A, indicating that ruxolitinib may have a therapeutic effect on PRCA.
    Journal
    |
    JAK2 (Janus kinase 2)
    |
    Jakafi (ruxolitinib) • cyclosporin A microemulsion
    2ms
    The complications of cyclosporine a in pediatric use and its effectiveness in treating pediatric congenital heart diseases-a meta analysis in combined with a retrospective clinical study. (PubMed, Front Pharmacol)
    Notably, our findings provide preliminary clinical evidence supporting the potential of immunosuppressive therapy to ameliorate CHD-associated cardiomyocyte maturation deficits. https://www.chictr.org.cn/, identifier ChiCTR2500103672.
    Retrospective data • Journal
    |
    CRP (C-reactive protein)
    |
    cyclosporin A microemulsion
    2ms
    The Impact of CYP3A4, CYP3A5, and ABCB1 Polymorphisms on Cyclosporine Concentration in Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation. (PubMed, Clin Transplant)
    Cyclosporine A (CsA) is used as graft-versus-host disease (GVHD) prophylaxis in allogeneic hematopoietic stem cell transplantation (HSCT)...In conclusion, patients carrying rs776746 or rs2740574 achieved higher CsA trough levels and may require lower initial dosing. Future research should assess whether genotype-guided CsA dosing improves achieving therapeutic levels and reduces early toxicity or suboptimal immunosuppression post-HSCT.
    Journal
    |
    ABCB1 (ATP Binding Cassette Subfamily B Member 1) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4) • CYP3A5 (Cytochrome P450 Family 3 Subfamily A Member 5)
    |
    cyclosporin A microemulsion
    3ms
    Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, Masonic Cancer Center, University of Minnesota | Trial completion date: Oct 2026 --> Feb 2027 | Trial primary completion date: Oct 2025 --> Feb 2026
    Trial completion date • Trial primary completion date
    |
    KMT2A (Lysine Methyltransferase 2A) • IKZF1 (IKAROS Family Zinc Finger 1)
    |
    MLL rearrangement
    |
    cyclophosphamide • fludarabine IV • cyclosporin A microemulsion
    3ms
    A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications (clinicaltrials.gov)
    P3, N=102, Recruiting, Bristol-Myers Squibb | Trial completion date: Dec 2033 --> Jun 2034
    Trial completion date
    |
    cyclosporin A microemulsion
    3ms
    CypA Mediates Non-Small Cell Lung Cancer Chemoresistance by Attenuating Ferroptosis via Stabilizing SLC7A11. (PubMed, Adv Sci (Weinh))
    Here, cyclophilin A (CypA) is identified as a critical mediator of cisplatin (DDP)/paclitaxel (DTX) resistance in NSCLC by suppressing ferroptosis, an iron-dependent form of regulated cell death...knockout of CypA or pharmacological inhibition with cyclosporine A (CsA) reverse resistant NSCLC cells to DDP/DTX both in vitro and in vivo by restoring ferroptosis...The study uncovers a CypA/SLC7A11/TRIM3 axis governing ferroptosis evasion in NSCLC chemoresistance and highlights CypA as a promising therapeutic target. Repurposing CsA to inhibit CypA represents a translatable strategy to overcome chemotherapy resistance, offering preclinical validation for improving outcomes in NSCLC patients.
    Journal
    |
    SLC7A11 (Solute Carrier Family 7 Member 11) • TRIM3 (Tripartite Motif Containing 3)
    |
    cisplatin • paclitaxel • cyclosporin A microemulsion
    3ms
    Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1) (clinicaltrials.gov)
    P3, N=62, Completed, Zambon SpA | N=220 --> 62
    Enrollment change
    |
    cyclosporin A microemulsion